BioSig Technologies, a medical technology company that provides unprecedented accuracy and precision in intracardiac signal visualization, is working with technical advisory partner Reified Labs to advance the research and development of an artificial intelligence (AI) medical device platform. announced that there will be
Recommended: AiThority interview with Bridget McInnis-Day, UiPath Chief Human Resources Officer
The platform’s underlying machine learning models are expected to be based on integrated medical datasets, starting with ECG and IECG data acquired by BioSig’s first product, the PURE EP™ platform. Electrophysiology-focused technology solutions developed under the terms of the partnership may be integrated into He PURE EP™ Technology for potential commercial applications.
Reified Labs, based in Cambridge, Massachusetts, is a provider of advanced artificial intelligence focused technical advisory services to the life sciences industry and is an award-winning computer scientist trained at Harvard and MIT. Led by Dr. Alexander D. Wisner Gross. Physicist, Entrepreneur, Writer. BioSig has filed multiple patent applications due to his previous collaboration with Reified, founded in 2019.1 and research publications2 For the first discovery in AI-enhanced ECG lead placement mapping.
On June 20, 2023, Dr. Wisner Gross delivered a keynote address at a gathering of distinguished clinical leaders in Rochester, Minnesota, exploring the exciting possibilities artificial intelligence brings to healthcare. In a talk titled “Unsupervised Medicine: The Next Wave of AI in Healthcare,” Dr. Wisner and his Gross reviewed recent research advances in unsupervised (or self-supervised) machine learning models. Such models appear to have dramatically accelerated overall progress towards artificial general intelligence (AGI), with one community claiming that with AGI’s expected arrival date only in the past two years, he could be expected to reach him from 2043. predicted to collapse in 2026. In describing how AGI and its applications are accelerating in the medical field, Dr. Wissner-Gros used a previous collaboration between Reified and BioSig as a case study.
Latest Insights: How to start rapid engineering with generative AI projects
“The cutting-edge research launched in early 2019 by this collaboration to lay the groundwork for AI is ahead of its time, and our initial findings have potentially valuable clinical implications worth exploring further. There may be some applications involved,” commented Chairman and CEO Kenneth L. Londoner. of BioSig Technologies, Inc.
“The application of AGI and digital signal processing to analyze signals from the so-called human ‘electrom’ (the set of all electrical and ionic currents in the human body) continues to be an important medical advance in physical disease.” We will continue to provide promising opportunities to realize It’s the peripheral nervous system,” said Dr. Wisner-Gross. “We look forward to future collaborations with BioSig.”
Latest interview insights: AiThority Interview with Abhay Parasnis, Founder and CEO of Typeface
[To share your insights with us, please write to sghosh@martechseries.com]
